Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting
A Consensus Document of the European Society of Cardiology Working Group onThrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]
Online Supplementary Material
G. Y. H. Lip, K. Huber (1), F. Andreotti (2), H. Arnesen (3), K. J. Airaksinen (4), T. Cuisset (5), P. Kirchhof (6), F. Marín (7)
(1) 3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria; (2) Institute of Cardiology, Gemelli University Hospital, Rome, Italy; (3) Department of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway; (4) Department of Medicine, Turku University Hospital, Turku, Finland; (5) Department of Cardiology, CHU Timone, Marseille, France; (6) Department of Cardiology and Angiology, Universitätsklinikum Münster, Münster, Germany; (7) Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Ctra Madrid-Cartagena s/n, Murcia, Spain
stenting, Acute coronary syndrome, percutaneous coronary intervention, warfarin, antithrombotic therapy, Arial fibrillation
There remains uncertainty over optimal antithrombotic management strategy for patients with atrial fibrillation (AF) presenting with an acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Clinicians need to balance the risk of stroke and thromboembolism against the risk of recurrent cardiac ischaemia and/or stent thrombosis, and the risk of bleeding. This consensus document comprehensively reviews the published evidence and presents a consensus statement on a ‘best practice’ antithrombotic therapy guideline for the management of antithrombotic therapy in such AF patients.